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ABSTRACT
Zidovudine is one of the first-line antiretroviral therapy regimen drug used to treat human immunodeficiency virus infected patients. Nail pigmentation 
associated with zidovudine therapy is seen in adults and children’s, mainly dark-skinned patients. This case attempts to draw attention among health-
care professionals concerning the non-serious adverse effect of nail pigmentation with zidovudine. In our case, the patient was counseled about 
this adverse effect without any change in zidovudine therapy. Even though this side effect is harmless and reversible, the psychological aspects of 
this visible side effect may reduce medication adherence and can also result in inessential investigations and management for misdiagnoses such as 
cyanosis and melanoma.
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INTRODUCTION
Zidovudine is one of the first-line antiretroviral therapy (ART) regimen 
drug used to treat human immunodeficiency virus (HIV) infected 
patients [1-3]. Nail pigmentation associated with zidovudine therapy 
is seen in adults and children’s, mainly dark-skinned patients [4]. 
This grayish blue discoloration of the nails seems to be reversible and 
comparatively dose-dependent [5-7]. The causal mechanism behind 
this unusual nail pigmentation by the drug is not clearly understood [7]. 
Although nail pigmentation is harmless, this side effect can affect the 
psychological well-being of the patient which can lead to non-adherence 
to the therapy. As zidovudine is one of the most commonly recommended 
ART drugs, it is essential to create awareness among patients about 
nail pigmentation-related to zidovudine. Herein, we report a case of 
zidovudine-induced thumbnails hyperpigmentation in an HIV positive 
patient coinfected with herpes zoster infection. This case tries to draw 
attention among health-care professionals concerning the non-serious 
adverse effect of nail pigmentation with zidovudine.
CASE REPORT
A 58-year-old male patient was admitted to the dermatology department 
of the hospital with a history of painful lesions on the left side of the face 
for 5 days. He also complained of hyperpigmentation of the thumbnails 
of both hands for 1 week. Antiretroviral therapy (lamivudine 150 mg, 
nevirapine 200 mg, and zidovudine 300 mg) was started for him from 
the past 10 months onward. In addition to ART therapy, he was on 
tablet cilnidipine (10 mg, once daily) for hypertension, human insulin 
(14–12–0 units/day), and neutral protamine Hagedorn 70%+human 
insulin 30% (0–0–10 units/day) for diabetes mellitus since 15 years.
He was averagely built, nourished with his general and systemic 
examinations were found to be normal. On cutaneous examination, 
there were fluid-filled blisters present on the left side of forehead 
extending to the left side of the frontoparietal part of the scalp. The 
lesions were associated with pricking pain and also few grouped vesicles 
were appeared on the erythematous base of the nasal bridge and lateral 
aspect of the left nose. Periorbital edema on the left eye with conjunctival 
congestion was associated with mucoid discharge. The thumbnails 
showed hyperpigmentation with no evidence of skin and mucous 
membrane involvement (Figs. 1 and 2). The complete blood count done 
and was revealed to be normal. The CD4 count was 210 cells/cumm and 
the enzyme-linked immunosorbent assay test for HIV was positive. On 
the basis of clinical findings and laboratory parameters, the diagnosis 
made was herpes zoster ophthalmicus infection secondary to the HIV 
infection. He was managed conservatively with injection betamethasone 
(4 mg, once daily), valacyclovir (1 gm, PO 3 times a day), and amoxicillin 
500 mg+clavulanic acid 125 mg (PO, 3 times a day) along with 
appropriate wound care (fusidic acid cream 2% w/w, 2 times a day and 
acyclovir eye ointment 5% w/w, 5 times a day).
However, the hyperpigmentation of the thumbnails cannot be 
explained. Thyroid profile done was found to be normal, and the 
Addison’s disease was also ruled out for this patient. The patient had 
no history of injury, or no triggering factors were noted for these 
thumbnails hyperpigmentation, so a detailed medication history was 
taken, as nearly 10–20% of the cutaneous hyperpigmentation cases 
account for the drug. It revealed that the patient was on antidiabetic 
and antihypertensive medications for 15 years and ART for 10 months. 
The patient had a safe medication history with antidiabetic and 
antihypertensive drugs. The thumbnails hyperpigmentation occurred 
after starting the ART therapy. Among the ART regimen the patient is 
administered, the drug zidovudine has case reports for causing nail 
hyperpigmentation.
The time temporal relationship between the initiation of zidovudine 
and following which development of hyperpigmentation of thumbnails 
of both hands could not be clarified by any coexisting medications, 
medical conditions or chemicals used. Hence, the final diagnosis of 
zidovudine-induced nail pigmentation in an HIV patient with secondary 
herpes zoster ophthalmicus infection was established. It was a probable 
cause for hyperpigmentation of the thumbnails due to zidovudine 
therapy in accordance with Naranjo score of five and the World Health 
Organization causality assessment system. This adverse event was 
classified as non-serious adverse drug reaction (ADR) according to the 
Hartwig ADR severity assessment scale, so no change in the therapy 
for the current case. The patient was counseled about this non-serious 
adverse event of zidovudine to avoid the medication nonadherence of 
the patient.
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in the case of the drug can be secondary deposition of the drug or 
its metabolites in the dermis making complexes with melanin or 
iron [7]. Animal studies demonstrated that there are elevated amounts 
of melanosomes in epidermal keratinocytes [4].
In this case, the thumbnails discoloration was noticed by the patient 
after the initiation of zidovudine therapy and this adverse event is a 
non-serious reaction, so he is continuing the same ART regimen.
CONCLUSION
Although this adverse effect is non-serious and reversible, the 
psychological aspects of this visible side effect may reduce medication 
adherence and can also result in inessential investigations and 
management for misdiagnoses such as cyanosis and melanoma. As 
many patients are on zidovudine therapy, so it is essential to create 
awareness among patients about nail pigmentation.
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Fig. 1: Hyperpigmentation of right hand thumb nail
Fig. 2: Hyperpigmentation of left hand thumb nail
DISCUSSION
Nail pigmentation due to zidovudine was first illustrated by Furth 
and Kazakis among two black patients [8]. Drugs could be the 
contributing factor in 10–20% of cutaneous hyperpigmentation cases, 
in addition to a variety of medical conditions [9,4]. The causative 
agents most commonly associated with discoloration of nails and 
skin are nonsteroidal anti-inflammatory drugs, antimalarials, 
amiodarone, chemotherapeutic agents, psychotropic drugs, zidovudine, 
tetracyclines, and heavy metals [9]. The nail pigmentation may appear 
with different clinical patterns such as either transverse bands, 
longitudinal bands, or diffuse discoloration [4]. According to the culprit 
drug, the hyperpigmentation pathogenesis and their clinical pattern 
may change [7]. The underlying mechanism behind nail pigmentation 
